Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants

SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies resilient to mutations in emerging Omicron subvariants. Y489 was identified as a site of virus vulnerability...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 4198 - 17
Main Authors Moriyama, Saya, Anraku, Yuki, Taminishi, Shunta, Adachi, Yu, Kuroda, Daisuke, Kita, Shunsuke, Higuchi, Yusuke, Kirita, Yuhei, Kotaki, Ryutaro, Tonouchi, Keisuke, Yumoto, Kohei, Suzuki, Tateki, Someya, Taiyou, Fukuhara, Hideo, Kuroda, Yudai, Yamamoto, Tsukasa, Onodera, Taishi, Fukushi, Shuetsu, Maeda, Ken, Nakamura-Uchiyama, Fukumi, Hashiguchi, Takao, Hoshino, Atsushi, Maenaka, Katsumi, Takahashi, Yoshimasa
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 14.07.2023
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies resilient to mutations in emerging Omicron subvariants. Y489 was identified as a site of virus vulnerability and a common footprint of broadly neutralizing antibodies against the subvariants. Multiple Y489-binding antibodies were encoded by public clonotypes and additionally recognized F486, potentially accounting for the emergence of Omicron subvariants harboring the F486V mutation. However, a subclass of antibodies broadly neutralized BA.4/BA.5 variants via hydrophobic binding sites of rare clonotypes along with high mutation-resilience under escape mutation screening. A computationally designed antibody based on one of the Y489-binding antibodies, NIV-10/FD03, was able to bind XBB with any 486 mutation and neutralized XBB.1.5. The structural basis for the mutation-resilience of this Y489-binding antibody group may provide important insights into the design of therapeutics resistant to viral escape. In this study, the authors isolated SARS-CoV-2 receptor binding site monoclonal antibodies resistant to Omicron mutations. An amino acid in the receptor binding domain, tyrosine-489, is a virus-vulnerable site and a common footprint of broadly neutralizing antibodies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-39890-8